Tenecteplase has a specificity for fibrin that is how many times higher compared to alteplase?

Tenecteplase is a thrombolytic agent that is engineered to have a higher specificity for fibrin compared to alteplase. This increased specificity enables tenecteplase to bind more selectively to fibrin in the clot, which may enhance its effectiveness in breaking down thrombi while minimizing the breakdown of circulating plasma fibrinogen. The correct answer signifies that tenecteplase has a specificity for fibrin that is 15 times higher than that of alteplase. This characteristic is crucial in clinical settings, as such selective targeting can lead to better outcomes for patients with conditions like acute myocardial infarction, where rapid and effective thrombolysis is essential. By understanding the comparative fibrin specificity between these two agents, practitioners can make more informed decisions regarding thrombolytic therapy in various clinical scenarios.